聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎疗效观察

Efficacy of peginterferon α-2b plus ribavirin for treating chronic hepatitis C

目的以普通干扰素(IFN)α-2b联合利巴韦林为对照,观察聚乙二醇干扰素(PEG-IFN)α-2b联合利巴韦林治疗慢性丙型肝炎(CHC)的临床疗效。方法成人CHC患者96例随机分为两组,每组48例,观察组给予PEGIFNα-2b,对照组给予IFNα-2b,均联合利巴韦林口服,疗程48周。观察两组早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)、持久病毒学应答(SVR)和安全性等方面的差异。结果观察组EVR率、ETVR率、SVR率均高于对照组(χ2分别=6.27、4.17、4.44,P均<0.05)。两组不良反应发生率差异无统计学意义(χ2=0.12,P>0.05)。结论PEG-IFNα-2b联合利巴韦林治疗CHC疗效优于普通干扰素联合利巴韦林,但SVR率需要进一步提高。

Objective To investigate the efficacy of long-acting interferon （peginterferon alfa-2b, PEG-IFNα-2b） plus ribavirin for treating chronic hepatitis C （CHC） in comparison with that of conventional interferon alfa-2b （IFNα-2b） plus ribavirin. Methods A total of 96 consecutive, treatment-naive, HCV RNA-positive patients with chronic hepatitis were randomly assigned to once weekly PEG-IFNα-2b （Observational group, n=48） or every other day IFNα-2b （Control group, n=48） plus ribavirin for 48 weeks. The rates of early-, end of treatment-, and sustained- virological response （VR） to- gether with the safety and adverse-event profiles between the two groups were compared. Results More patients in obser- vational group than control group achieved an early VR （X^2=6.27,P〈0.05）, an end of treatment VR （X^2=4.17,P〈0.05） and a sustained VR （X^2=4.44, P〈0.05 ）. The safety profile was similar between the two groups （X^2=0.12, P〉O.05 ）. Conclu- sions PEG-IFNα-2b plus ribavirin is more effective than IFNα-2b plus ribavirin for treating CHC, but its sustained VR rate needs further improvement.